EUCTR2010-022758-18-AT进行中（未招募）不适用
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy - UNITI 1
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 703
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Be a man or woman = 18 years of age.
- •2. Have Crohn’s disease or fistulizing Crohn’s disease of at least 3 months’ duration, with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy.
- •3. Have active Crohn’s disease, defined as a baseline CDAI score of = 220 and = 450.
- •4. Have received infliximab, adalimumab, or certolizumab pegol at a dose approved for the treatment of Crohn’s disease and
- •a. Did not respond initially;
- •b. Responded initially but then lost response with continued therapy;
- •c. Were intolerant to the medication.
- •5. Adhere to the following requirements for concomitant medication for the treatment of Crohn’s disease. The following medications are permitted provided doses meeting the requirements below are stable for or have been discontinued at least 3 weeks prior to baseline (Week 0), unless otherwise specified.
- •a. Oral 5-ASA compounds.
- •b. Oral corticosteroids at a prednisone-equivalent dose of = 40 mg/day or = 9 mg/day of budesonide.
- •c. Antibiotics being used as a primary treatment of Crohn’s disease.
- •d. Subjects receiving conventional immunomodulators must have been taking them for = 12 weeks, and on a stable dose for a least 4 weeks prior to baseline.
- •6. Have screening laboratory test results within the parameters mentioned in the protocol:
- •7. Are considered eligible according to the following TB screening criteria:
- •a. Have no history of latent or active TB prior to screening. Exceptions are made for subjects currently receiving treatment for latent TB, if there is no evidence of active TB, or who have a history of latent TB and documentation of having completed adequate treatment for latent TB within 3 years prior to the first administration of study agent. It is the responsibility of the investigator to verify the adequacy of previous TB treatment and provide appropriate documentation.
- •b. Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.
- •c. Have had no recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study agent.
- •d. Within 2 months prior to the first administration of study agent, either have negative QuantiFERON-TB Gold test, or have a newly identified positive QuantiFERON-TB Gold test in which active TB has been ruled out, and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study agent. A negative tuberculin skin test is additionally required if the QuantiFERON-TB gold test is not approved/registered in that country. The QuantiFERON-TB Gold In-Tube test is not required at screening for subjects with a history of latent TB and appropriate treatment as described in 7a.
- •e. Have a chest radiograph, taken within 3 months prior to the first administration of study agent and read by a qualified radiologist, with no evidence of current active TB or old inactive TB.
- •8. If a woman, before entry she must be:
- •a. Postmenopausal, defined as
- •1) > 45 years of age with amenorrhea for at least 18 months,
- •2) > 45 years of age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level > 40 IU/mL
- •b. Menstrual
- •1) Surgically
排除标准
- •1. Has complications of Crohn’s disease such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation that might be anticipated to require surgery, could preclude the use of the CDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with ustekinumab.
- •2. Currently has or is suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks prior to baseline, or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery. Subjects with active fistulas may be included if there is no anticipation of a need for surgery and there are currently no abscesses identified.
- •3. Has had any kind of bowel resection within 6 months or any other intra-abdominal surgery within 3 months prior to baseline.
- •4. Has a draining stoma or ostomy.
- •5. Has received any of the prescribed medications or therapies within the specified period (mentioned in the protocol).
- •6. Have a stool culture or other examination positive for an enteric pathogen, including Clostridium difficile toxin, in the last 4 months unless a repeat examination is negative and there are no signs of ongoing infection with that pathogen.
- •7. Has previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874).
- •8. Has received a Bacille Calmette-Guérin (BCG) vaccination within 12 months or any other live bacterial or live viral vaccination within 12 weeks of baseline.
- •9. Has a history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection, recurrent urinary tract infection, or open, draining, or infected skin wounds or ulcers.
- •10. Has current signs or symptoms of infection. Established nonserious infections need not be considered exclusionary at the discretion of the investigator.
- •11. Has a history of serious infection, including any infection requiring hospitalization or IV antibiotics, for 8 weeks prior to baseline.
- •12. Has evidence of a herpes zoster infection = 8 weeks prior to baseline.
- •13. Has a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening. Refer to inclusion criteria for information regarding eligibility with a history of latent TB.
- •14. Has evidence of current active infection, including but not limited to TB (exceptions see protocol).
- •15. Has or ever has had a nontuberculous mycobacterial infection or serious opportunistic infection.
- •16. Is known to be infected with HIV, hepatitis B, or hepatitis C.
- •17. Has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or signs and symptoms thereof.
- •18. Has a transplanted organ.
- •19. Has a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
- •20. Has any known malignancy or has a history of malignancy.
- •21. Has previously undergone allergy immunotherapy for prevention of anaphylactic reactions.
- •22. Is unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy (RT/CT)EUCTR2004-002016-28-ITAMGE
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s DiseaseEUCTR2010-022760-12-ITJanssen-Cilag International N.V.1,281
进行中（未招募）
不适用
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate theEfficacy and Safety of Weekly Doses of Palifermin (Recombinant HumanKeratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis inSubjects With Advanced Head and Neck Cancer Receiving Radiotherapy WithConcurrent Chemotherapy (RT/CT). - Palifermin 2002402EUCTR2005-000213-35-ITAMGEN S.P.A.180
进行中（未招募）
1 期
An Phase 3 clinical study comparing a vector transferring the gene for Glucose-6-Phosphatase with placebo in adults with Glycogen Storage Disease Type Ia.EUCTR2020-004184-12-PTltragenyx Pharmaceutical Inc.50
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD TherapyMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859Psoriatic ArthritisEUCTR2019-002021-29-ESGilead Sciences Inc.390